Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Objectives All microsomal cytochrome P450s enzymes, including those that metabolize the majority of clinically used drugs, require electron transfer through P450 oxidoreductase (POR). Mutations in human POR cause altered steroidogenesis and congenital malformations, but the clinical effects on drug metabolism are unclear. We examined the effects of POR sequence variants on two drug-metabolizing P450 enzymes, CYP1A2 and CYP2C19. Methods Our previous sequencing of the human POR gene in POR-deficient patients and in 842 normal individuals identified 35 sequence variants. We expressed these 35 POR sequence variants in bacteria, reconstituted them with the CYP enzymes in vitro, and assayed their activities with human CYP1A2 and CYP2C19. Results POR variants affected the activities of these enzymes to different extents. Disease-causing POR mutations A287P and R457H diminished catalysis by CYP1A2 and CYP2C19 to barely detectable levels. POR A503V, a polymorphism found in 28% of alleles in the normal population, had 85% of wild-type activity with CYP1A2 and 113% of wild-type activity with CYP2C19. Q153R, a disease-causing mutation that severely impaired steroidogenic activity and cytochrome c reduction, increased the activity of CYP1A2 to 144% and CYP2C19 activity to 284% of control. Conclusion The activity of individual POR mutants may vary greatly depending on the electron recipient used to assay activity. Thus, the activity of a POR mutant to support catalysis by a particular P450…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Considering all available data from previous reports [4,46,47] and multiple functional assays described in this manuscript, we suggest that rs17853284, the variant causing amino acid change P228L in POR, is a disease-causing variant, whose effect will be prominent when present together with another variant of POR on the second allele that has a severe impact on POR activities.”
From Loss of Protein Stability and Function Caused by P228L Variation in NADPH-Cytochrome P450 Reductase Linked to Lower Testosterone Levels (2022) · cites this paper as [46]
In the citing paper
“but has no measurable effect on the activities of P450c21 (306) or hepatic CYP1A2 or CYP2C19 (307), but it reduces the activities of CYP2D6 and CYP3A4 to metabolize important drugs in vitro (308, 309).”
From The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders (2011) · cites this paper as [307]
In the citing paper
“A survey of 35 POR variants with the human hepatic enzymes CYP1A2 or CYP2C19 found substantial differences among the POR variants studied, including some (notably Q153R) that increased activity”
From Steroidogenic electron-transfer factors and their diseases (2021) · cites this paper as [81]
Citations
Cites
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Evans, W. E., & Relling, M. V. (1999) · Science · doi:10.1126/science.286.5439.487 · Cited by 2,475
Miroux, B., & Walker, J. E. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0399 · Cited by 1,959
Nelson, D. R., Zeldin, D. C., Hoffman, S. M., Maltais, L. J., Wain, H. M., & Nebert, D. W. (2004) · Pharmacogenetics · doi:10.1097/00008571-200401000-00001 · Cited by 1,027
Summary of information on human CYP enzymes: human P450 metabolism data
Rendic, S. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001392 · Cited by 820
Moving towards individualized medicine with pharmacogenomics
Evans, W. E., & Relling, M. V. (2004) · Nature · doi:10.1038/nature02626 · Cited by 768
Bertz, R. J., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 755
Wang, M., Roberts, D. L., Paschke, R., Shea, T. M., Masters, B. S. S., & Kim, J.-J. P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.16.8411 · Cited by 744
Pharmacogenomics and Individualized Drug Therapy
Eichelbaum, M., Ingelman-Sundberg, M., & Evans, W. E. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104724 · Cited by 720
Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions: A Systematic Review
Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K., & Sadee, W. (2001) · JAMA · doi:10.1001/jama.286.18.2270 · Cited by 705
Ingelman-Sundberg, M. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.02.007 · Cited by 676
Lu, A. Y. H., Junk, K. W., & Coon, M. J. (1969) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)83427-5 · Cited by 577
Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome
Flück, C. E., Tajima, T., Pandey, A. V., Arlt, W., Okuhara, K., Verge, C. F., Jabs, E. W., Mendonça, B. B., Fujieda, K., & Miller, W. L. (2004) · Nature Genetics · doi:10.1038/ng1300 · Cited by 509
Self-citationArlt, W., Walker, E. A., Draper, N., Ivison, H. E., Ride, J. P., Hammer, F., Chalder, S. M., Borucka-Mankiewicz, M., Hauffa, B. P., Malunowicz, E. M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16503-3 · Cited by 345
Huang, N., Pandey, A. V., Agrawal, V., Reardon, W., Lapunzina, P. D., Mowat, D., Jabs, E. W., Vliet, G. V., Sack, J., Flück, C. E., et al. (2005) · The American Journal of Human Genetics · doi:10.1086/429417 · Cited by 336
Self-citationMinireview: Regulation of Steroidogenesis by Electron Transfer
Miller, W. L. (2005) · Endocrinology · doi:10.1210/en.2005-0096 · Cited by 324
Self-citationPharmacogenomics: Challenges and Opportunities
Roden, D. M., Altman, R. B., Benowitz, N. L., Flockhart, D. A., Giacomini, K. M., Johnson, J. A., Krauss, R. M., McLeod, H. L., Ratain, M. J., Relling, M. V., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-10-200611210-00007 · Cited by 282
Henderson, C. J., Otto, D. M. E., Carrie, D., Magnuson, M. A., McLaren, A. W., Rosewell, I., & Wolf, C. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212087200 · Cited by 258
The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug Response
Giacomini, K. M., Brett, C. M., Altman, R. B., Benowitz, N. L., Dolan, M. E., Flockhart, D. A., Johnson, J. A., Hayes, D. F., Klein, T., Krauss, R. M., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100087 · Cited by 242
Yamazaki, H., Nakamura, M., Komatsu, T., Ohyama, K., Hatanaka, N., Asahi, S., Shimada, N., Guengerich, F. P., Shimada, T., Nakajima, M., et al. (2002) · Protein Expression and Purification · doi:10.1006/prep.2001.1578 · Cited by 233
Shen, A. L., O'Leary, K. A., & Kasper, C. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111408200 · Cited by 225
NADPH-Cytochrome P450 Oxidoreductase
Hubbard, P. A., Shen, A. L., Paschke, R., Kasper, C. B., & Kim, J.-J. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101731200 · Cited by 216
Huang, N., Agrawal, V., Giacomini, K. M., & Miller, W. L. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711621105 · Cited by 198
Self-citationCytochrome P450: What Have We Learned and What Are the Future Issues?
Peter Guengerich, F. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-120033996 · Cited by 193
Otto, D. M. E., Henderson, C. J., Carrie, D., Davey, M., Gundersen, T. E., Blomhoff, R., Adams, R. H., Tickle, C., & Wolf, C. R. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.17.6103-6116.2003 · Cited by 189
Sandhu, P., Guo, Z. Y., Baba, T., Martin, M. V., Tukey, R. H., & Guengerich, F. P. (1994) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1994.1099 · Cited by 184
The Biochemistry of Drug Metabolism – An Introduction: Part 2. Redox Reactions and Their Enzymes
Testa, B., & Krämer, S. D. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790032 · Cited by 171
Fukami, M., Horikawa, R., Nagai, T., Tanaka, T., Naiki, Y., Sato, N., Okuyama, T., Nakai, H., Soneda, S., Tachibana, K., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0810 · Cited by 155
Organization of multiple cytochrome P450s with NADPH-cytochrome P450 reductase in membranes
Backes, W. L., & Kelley, R. W. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(03)00031-7 · Cited by 151
Testa, B., & Krämer, S. D. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790169 · Cited by 140
Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase
Pandey, A. V., Kempná, P., Hofer, G., Mullis, P. E., & Flück, C. E. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0245 · Cited by 132
The Biochemistry of Drug Metabolism – An Introduction: Part 1. Principles and Overview
Testa, B., & Krämer, S. D. (2006) · Chemistry & Biodiversity · doi:10.1002/cbdv.200690111 · Cited by 128
The human genome project and novel aspects of cytochrome 450 research
Ingelman‐Sundberg, M. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2005.01.030 · Cited by 125
Genetic and clinical features of P450 oxidoreductase deficiency
Scott, R. R., & Miller, W. L. (2008) · Hormone Research in Paediatrics · doi:10.1159/000114857 · Cited by 115
Self-citationAdachi, M., Tachibana, K., Asakura, Y., Yamamoto, T., Hanaki, K., & Oka, A. (2004) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30169 · Cited by 110
Hart, S. N., Wang, S., Nakamoto, K., Wesselman, C., Li, Y., & Zhong, X.-B. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f2f121 · Cited by 98
Genetic basis of toxic reactions to drugs and chemicals
Cascorbi, I. (2005) · Toxicology Letters · doi:10.1016/j.toxlet.2005.10.015 · Cited by 96
Trubetskoy, O. V., Gibson, J. R., & Marks, B. D. (2005) · SLAS DISCOVERY · doi:10.1177/1087057104269731 · Cited by 89
The Evolving Role of Drug Metabolism in Drug Discovery and Development
Yengi, L. G., Leung, L. Y., & Kao, J. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9217-9 · Cited by 86
Scott, R. R., Gomes, L. G., Huang, N., Van Vliet, G., & Miller, W. L. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2345 · Cited by 79
Self-citationFukami, M., Hasegawa, T., Horikawa, R., Ohashi, T., Nishimura, G., Homma, K., & Ogata, T. (2006) · Pediatric Research · doi:10.1203/01.pdr.0000195825.31504.28 · Cited by 79
Differential Inhibition of CYP17A1 and CYP21A2 Activities by the P450 Oxidoreductase Mutant A287P
Dhir, V., Ivison, H. E., Krone, N., Shackleton, C. H. L., Doherty, A. J., Stewart, P. M., & Arlt, W. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0066 · Cited by 78
Ribes, V., Otto, D. M. E., Dickmann, L., Schmidt, K., Schuhbaur, B., Henderson, C., Blomhoff, R., Wolf, C. R., Tickle, C., & Dollé, P. (2007) · Developmental Biology · doi:10.1016/j.ydbio.2006.10.032 · Cited by 73
Wu, L., Gu, J., Cui, H., Zhang, Q.-Y., Behr, M. J., Fang, C., Weng, Y., Kluetzman, K., Swiatek, P. J., Yang, W., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.073353 · Cited by 71
The association of cytochrome P-450 and NADPH-cytochrome P-450 reductase in phospholipid membranes
Miwa, G. T., & Lu, A. Y. H. (1984) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(84)90337-0 · Cited by 67
Antley-Bixler syndrome: Case report and review of the literature
CRISPONI, G., PORCU, C., & PIU, M. E. (1997) · Clinical Dysmorphology · doi:10.1097/00019605-199701000-00011 · Cited by 65
Dierks, E. A., Davis, S. C., & Ortiz de Montellano, P. R. (1998) · Biochemistry · doi:10.1021/bi972458s · Cited by 59
The journey from NADPH-cytochrome P450 oxidoreductase to nitric oxide synthases
Masters, B. S. S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.165 · Cited by 59
Marohnic, C. C., Panda, S. P., Martásek, P., & Masters, B. S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607095200 · Cited by 57
Overexpression and Purification of the Membrane-Bound Cytochrome P450 2B4
Sarıbaş, A. S., Gruenke, L. D., & Waskell, L. A. (2001) · Protein Expression and Purification · doi:10.1006/prep.2000.1377 · Cited by 52
The syndrome of multisynostotic osteodysgenesis with long‐bone fractures
DeLozier, C. D., Antley, R. M., Williams, R., Green, N., Heller, R. M., Bixler, D., Engel, E., & Optiz, J. M. (1980) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320070322 · Cited by 44
Marks, B. D., Smith, R. W., Braun, H. A., Goossens, T. A., Christenson, M. J., Ozers, M. S., Lebakken, C. S., & Trubetskoy, O. V. (2002) · Assay and Drug Development Technologies · doi:10.1089/154065802761001329 · Cited by 39
Cheng, D., Kelley, R. W., Cawley, G. F., & Backes, W. L. (2003) · Protein Expression and Purification · doi:10.1016/j.pep.2003.08.009 · Cited by 28
Cited by
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Self-citationNADPH P450 oxidoreductase: Structure, function, and pathology of diseases
Pandey, A. V., & Flück, C. E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.010 · Cited by 279
Šrejber, M., Navrátilová, V., Paloncýová, M., Bazgier, V., Berka, K., Anzenbacher, P., & Otyepka, M. (2018) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2018.03.002 · Cited by 190
de Jonge, H., Metalidis, C., Naesens, M., Lambrechts, D., & Kuypers, D. R. J. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.77 · Cited by 145
Gomes, A. M., Winter, S., Klein, K., Turpeinen, M., Schaeffeler, E., Schwab, M., & Zanger, U. M. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.7 · Cited by 125
Metadata
- Authors
- Agrawal, V., Huang, N., & Miller, W. L.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Miller, Walter L.
- Venue
- Pharmacogenetics and Genomics
- Published
- 2008-07
- Volume
- 18
- Issue
- 7
- Pages
- 569-576
- ISSN
- 1744-6872 (ISSN-L)
- OpenAlex
- W2077782498
- Semantic Scholar
- af016df9ce2ad1c6926bb06668a0312717109fc4
- Cited by
- 117
- References
- 52
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 6 · 2023: 7 · 2022: 5 · 2021: 3 · 2020: 3 · 2019: 6 · 2018: 5 · 2017: 6 · 2016: 4 · 2015: 8 · 2014: 8 · 2013: 9 · 2012: 9
- FWCI
- 10.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacogenetics and Genomics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of General Medical Sciences (R01GM073020)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Physical Sciences › Chemistry › Inorganic Chemistry › Metal-Catalyzed Oxygenation Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- cytochrome P450 oxidoreductase, CYP1A2, CYP2C19, drug metabolism
- MeSH terms
- Animals, Aryl Hydrocarbon Hydroxylases, Catalysis, Cell Membrane, Enzyme Activation, Escherichia coli, Humans, Kinetics, Inactivation, Metabolic, Models, Biological, NADPH-Ferrihemoprotein Reductase, Pharmacogenetics, Substrate Specificity, Transformation, Bacterial, Cytochrome P-450 CYP1A2, Polymorphism, Single Nucleotide, Mutant Proteins, Rats, Cytochrome P-450 CYP2C19
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.